The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | The PRISM score: improving risk stratification of newly diagnosed AML treated with ven-based therapy
In this interview, Curtis Lachowiez, MD, Oregon Health & Science University, Portland, OR, discusses the development of the Prognostic Risk Integration for Survival Modeling (PRISM) score to improve risk stratification in newly diagnosed acute myeloid leukemia (AML) treated with lower-intensity venetoclax (ven)-based regimens. Dr Lachowiez highlights that around half of patients classified as favorable-risk by the currently used 4-gene molecular prognostic risk score (mPRS) were reclassified to intermediate- or adverse-risk by the PRISM model, which resulted in better separation of survival curves and improvement in survival discrimination and modeling. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
